Cardiovascular Diseases Clinical Trial
Official title:
Effect of the Antioxidant Micronutrients of Rapeseed Oil on the Prevention of Cardiovascular Diseases
| Verified date | March 2010 |
| Source | University Hospital, Clermont-Ferrand |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | France: Ministry of Health |
| Study type | Interventional |
The purpose of this study is to assess the effect of optimized oil (enriched with
micronutriments) on the prevention on cardiovascular diseases.
Randomised crossover dietary intervention study:
The main objective of the clinical study is to investigate the effect of the consumption of
an "optimized" rapeseed oil on the lipid metabolism of volunteers as compared with the
consumption of a "reference" oil.
Post prandial study:
The second objective of the clinical study is to investigate the effect of the consumption
of an "optimized" rapeseed oil on the biomarkers of oxidative stress during post prandial
period as compared with the consumption of a "reference" oil.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | July 2009 |
| Est. primary completion date | July 2009 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Male |
| Age group | 30 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Male - Age : 30 to 65 - Body mass index between 25 and 30 kg/m² - Weight lower than 110 kg - Subject considered as normal after clinical examination and medical questionnaire - Subject giving his written informed consent - Subject willing to comply with the study procedures - Affiliated to National Health Insurance Exclusion Criteria: - Biological results judged abnormal by investigator - Positive serologies to HIV or HCV - Previous medical and/or surgery judged by the investigator as incompatible with the study - Taking medicine: hypocholesterolemic,beta blockers, IEC, - Diabetes1 and 2 - High blood pressure - Digestive, cardiovascular, renal, liver, tumor or thyroid diseases in the last 5 years - Infectious or inflammatory diseases in the last 5 years - Previous heavy intestine surgery (except appendectomy) - Triglycerides> 4 g/L - Dyslipidemia: HDL cholesterol< 0.4 g/L or LDL/HDL>6.25 - blood donation done less than 2 month before the start of the study - Particular diet: vegetarian, vegan... - Anormal dietary habits - Consumption of food complements: antioxidant, ... - intense physical exercise practise (>5 h per week) - Tobacco, alcohol:more than 30 g of alcohol/day, i.e.3 glasses/day, smoking > 5 cigarettes /day - No affiliated to National Health Insurance people - Refusal to sign informed consent - Refusal to be registered on the National Volunteers Data file - Currently participating or who having got 4500 E in this year before to have participated in another clinical trial |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| France | CRNH Auvergne | Clermont-Ferrand |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Clermont-Ferrand | Centre de Recherche en Nutrition Humaine d'Auvergne, Institut National de la Recherche Agronomique, ITERG, Lesieur, Unilever R&D |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | HDL-Cholestérol | study 1 | Yes | |
| Secondary | Biomarkers of the oxidative stress every 3 weeks Biomarkers of the oxidative stress during the post prandial period | every 3 weeks, during the post prandial period | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
| Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
| Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
| Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
| Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
| Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
| Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
| Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
| Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
| Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
| Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
| Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
| Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
| Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
| Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
| Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|